Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention.
Tatsuhiko OtsukaYasushi UekiRaminta KavaliauskaiteThomas ZanchinSarah BärStefan StorteckyThomas PilgrimMarco ValgimigliBernhard MeierDik HegStephan WindeckerLorenz RäberPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
Among selected CCS patients undergoing PCI with DES, SAPT with prasugrel was not associated with an excess of ischemic events compared with standard DAPT. No difference in bleeding was observed either. The results may serve as the basis for larger trials assessing the potential benefits and risks of SAPT.
Keyphrases
- percutaneous coronary intervention
- antiplatelet therapy
- patients undergoing
- st segment elevation myocardial infarction
- acute coronary syndrome
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- atrial fibrillation
- coronary artery bypass grafting
- human health
- coronary artery bypass
- ischemia reperfusion injury
- heart failure
- climate change
- brain injury